Jupiter Neurosciences 1-for-75 Reverse Stock Split

Jupiter Neurosciences, Inc. (Nasdaq: JUNS), a clinical-stage biopharmaceutical company, announced on August 5, 2026, that its board of directors approved a 1-for-75 reverse stock split of its common stock. The reverse split, approved by stockholders at the annual meeting on July 22, 2026, will take effect at 4:01 p.m. Eastern Time on August 6, 2026. Trading on a split-adjusted basis will begin on The Nasdaq Capital Market on August 7, 2026, under the ticker symbol JUNS with a new CUSIP number. The reverse split will reduce outstanding shares from approximately 57,756,143 to approximately 770,081. No fractional shares will be issued; holders of fractional shares will receive cash payments. The company intends the reverse split to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement. Jupiter's pipeline includes JOTROL, a resveratrol formulation in Phase IIa for Parkinson's disease, and ALA-002, a psychedelic compound licensed from PharmAla Biotech for treatment-resistant PTSD and anxiety.